Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Laurus Labs
LAURUSLABS
Laurus Labs
Digital Transformation And Affordable Generics Will Expand Global Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
05 Jul 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
₹1,025.00
16.1% undervalued
intrinsic discount
15 Aug
₹859.70
Loading
1Y
96.9%
7D
3.4%
Author's Valuation
₹1.0k
16.1% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
₹1.0k
16.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
92b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹91.6b
Earnings ₹17.4b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.84%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹17.42b
Earnings '28
x
44.42x
PE Ratio '28
=
₹773.80b
Market Cap '28
₹773.80b
Market Cap '28
/
527.65m
No. shares '28
=
₹1.47k
Share Price '28
₹1.47k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹1.02k
Fair Value '25